These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 32399812)

  • 1. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States.
    Kabadi SM; Goyal RK; Nagar SP; Kaye JA; Davis KL
    Cancer Med; 2019 Jul; 8(8):3803-3810. PubMed ID: 31144473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
    Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
    Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
    Cheung MC; Mittmann N; Owen C; Abdel-Samad N; Fraser GAM; Lam S; Crump M; Sperlich C; van der Jagt R; Prica A; Couban S; Woyach JA; Ruppert AS; Booth AM; Mandrekar SJ; McDonald G; Shepherd LE; Yen H; Chen BE; Hay AE
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):766-774. PubMed ID: 34334330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
    Kabadi SM; Byfield SD; LE L; Olufade T
    Anticancer Res; 2021 Feb; 41(2):927-936. PubMed ID: 33517299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
    Huntington SF; Manzoor BS; Jawaid D; Puckett JT; Emechebe N; Ravelo A; Kamal-Bahl S; Doshi JA
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1106-1116. PubMed ID: 39046941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
    Collett L; Howard DR; Munir T; McParland L; Oughton JB; Rawstron AC; Hockaday A; Dimbleby C; Phillips D; McMahon K; Hulme C; Allsup D; Bloor A; Hillmen P
    Trials; 2017 Aug; 18(1):387. PubMed ID: 28830517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C; Pitt M; Moxham T; Stein K
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
    Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
    Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
    Irwin D; Wilson K; Thompson S; Choudhry A
    Curr Med Res Opin; 2021 Apr; 37(4):623-628. PubMed ID: 33563073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
    Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
    JCO Oncol Pract; 2024 Aug; 20(8):1132-1139. PubMed ID: 38626366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
    Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
    Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
    Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
    Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel.
    Weil C; Chodick G; Shalev V; Kan I; Afik R; Cohen R; Sail K; Herishanu Y
    Leuk Lymphoma; 2021 May; 62(5):1136-1145. PubMed ID: 33305641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
    Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
    Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
    Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF
    Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.